Share

CLINICAL TRIAL SEARCH RESULTS

NEW SEARCH
 Number: 201303012 Principal Investigator: Schroeder, Mark
Title: Phase I/II Trial of Intravenous Azacitidine in Patients Undergoing Matched Unrelated Stem Cell Transplantation
Description: This research study aims to discover the side effects and highest dose of a drug called azacitidine that can be given after a stem cell transplant to help prevent or minimize the effects of graft-versus-host disease (GVHD). We will also look at the way azacitidine might affect whether or how a pers...MORE
___________________________________________________________________________________________________
 Number: 201210102 Principal Investigator: Welch, John
Title: Genomic Predictors of Decitabine Response in AML/MDS
Description: The purpose of this research study is to identify genetic markers which will help us predict who will respond to treatment with a drug called decitabine and who will not. Typically, between 20 and 30% of patients with AML and MDS will achieve a complete response with decitabine, while the remaining...MORE
___________________________________________________________________________________________________
 Number: 201108378 Principal Investigator: Pusic, Iskra
Title: Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and High-Risk Myelodysplastic Syndrome
Description: The goal of this study is to determine the best dose of decitabine given after a transplant as maintenance therapy. We will also evaluate how effective decitabine is in getting rid of remaining disease and providing disease control, by allowing the graft (donor T-cells) to attack and control the ...MORE
___________________________________________________________________________________________________
 Number: 201107117 Principal Investigator: Vij, Ravi
Title: A Phase I Trial of Carfilzomib in Adult Patients with Relapsed Acute Myeloid and Acute Lymphoblastic Leukemia
Description: You may be asked to participate in this study if you have Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL) and your AML or ALL has come back after chemotherapy. The goal of this study is to determine the best dose of carfilzomib for treatment of these cancers....MORE
___________________________________________________________________________________________________
 Number: 201104323 Principal Investigator: Uy, Geoffrey
Title: A Pilot Study of G-CSF to Disrupt the Bone Marrow Microenvironment in Relapsed or Refractory Acute Lymphoblastic Leukemia
Description: The purpose of this research study is to see whether G-CSF given in combination with ifosfamide, etoposide, and dexamethasone is safe in treating ALL....MORE
___________________________________________________________________________________________________
 Number: 201011810 Principal Investigator: Vij, Ravi
Title: Phase II Trial of High Dose Lenalidomide in Patients with Myelodysplastic Syndrome Refractory to Hypomethylating Agents
Description: The purpose of this research study is to see how patients with MDS that is not responsive to standard treatment respond to high dose lenalidomide followed by low dose lenalidomide....MORE
___________________________________________________________________________________________________
 Number: 201102463 Principal Investigator: Fehniger, Todd
Title: KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor
Description: This study is investigating a newer donor selection factor, KIR genotyping, in addition to HLA testing and other donor selection factors....MORE
___________________________________________________________________________________________________
 Number: CTSU E2906 Principal Investigator: Uy, Geoffrey
Title: Phase III Randomized Trial of Clofarabine as Induction and Post- Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >= 60 Years)
Description: This trial is studying clofarabine to see how well it works compared with daunorubicin hydrochloride and cytarabine when followed by decitabine or observation in treating older patients with newly diagnosed acute myeloid leukemia....MORE
___________________________________________________________________________________________________
 Number: CTSU CIRB S1203 Principal Investigator: Uy, Geoffrey
Title: A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (IA+V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)
Description: The purpose of this study is to compare the effects, good and/or bad of three drug combinations. We want to see if the study treatments will get rid of leukemia cells and keep them from coming back to prepare a patient who may benefit from stem cell transplant....MORE
___________________________________________________________________________________________________
 Number: CALGB E1912 Principal Investigator: Bartlett, Nancy
Title: A Randomized Phase III Study of Ibrutinib (PCI-32765)-based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)
___________________________________________________________________________________________________
 Number: CALGB A041202 Principal Investigator: Bartlett, Nancy
Title: A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients (= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)
Description: The purpose of this study is to compare the effects, good and/or bad, of the drug ibrutinib, either alone or in combination with the drug rituximab, with the standard treatment for this disease. The standard treatment is chemotherapy with the drug bendamustine in combination with the drug rituxima...MORE
___________________________________________________________________________________________________
 Number: CALGB 10701 Principal Investigator: Uy, Geoffrey
Title: A Phase II Study of Dasatanib (Sprycel®) (IND #73969, NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years with Newly Diagnosed PH+ Acute Lymphoblastic Leukemia by CALGB, ECOG, and SWOG
Description: The purpose of this study is find out what effects (good and bad) an experimental drug known as dasatinib has on patients and their leukemia....MORE
___________________________________________________________________________________________________
 Number: 201310013 Principal Investigator: Wagner-Johnston, Nina
Title: An Open-Label, Phase I, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0853 in Patients with Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia
Description: The purpose of this study is to test the safety of an experimental drug (GDC-0853, the study drug) to determine a safe and tolerated dose, how often it should be taken, how well patients with cancer can tolerate this experimental drug, and measure how your body processes the study drug at different ...MORE
___________________________________________________________________________________________________
 Number: 201212112 Principal Investigator: Uy, Geoffrey
Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare Efficacy and Safety of Oral Azacitidine plus Best Supportive Care versus Best Supportive Care as Maintenance Therapy in Subjects with Acute Myeloid Leukemia in Complete Remission
Description: The purpose of the study is to demonstrate if maintenance therapy with oral azacitidine improves overall survival (OS) compared with placebo in subjects with AML, age = 55 years, who have achieved first complete remission following chemotherapy....MORE
___________________________________________________________________________________________________
 Number: 201210068 Principal Investigator: Uy, Geoffrey
Title: Phase III, Multicenter, Randomized, Trial of CPX-351 (Cytarabine: Daunorubicin) Liposome Injection versus Cytarabine and Daunorubicin in Patients 60-75 Years of Age with Untreated High Risk (Secondary) AML
Description: This study is designed to help us learn more about the investigational study drug, CPX-351, in elderly patients who are newly diagnosed with high risk (secondary) leukemia and have not received any treatment for the disease. Through this study, we plan to learn how safe CPX-351 is and how effective...MORE
___________________________________________________________________________________________________
 Number: 201206065 Principal Investigator: Uy, Geoffrey
Title: A Phase I, open, dose escalation trial with BI 836858 in patients with refractory or relapsed acute myeloid leukemia
Description: The purpose of this research study is to identify the highest dose of the study drug BI 836858 that does not cause unacceptable side effects and to obtain information on the safety and effectiveness of BI 836858....MORE
___________________________________________________________________________________________________
 Number: 201205111 Principal Investigator: Fehniger, Todd
Title: A Phase 1/2 Study of CNDO-109-Activated Allogeneic Natural Killer Cells in Patients with High Risk Acute Myeloid Leukemia in First Complete Remission (CR1)
Description: This study is being done to evaluate a drug called CNDO-109 Activated Allogeneic Natural Killer Cells and how patients with Acute Myeloid Leukemia (AML) respond when given this therapy....MORE
___________________________________________________________________________________________________
 Number: 201204052 Principal Investigator: DiPersio, John
Title: A randomized, prospective, double blind, placebo-controlled, phase 3 study of US-ATG-F prophylaxis as a supplement to standard of care prophylaxis to prevent moderate to severe chronic GVHD in adult acute myeloid leukemia, acute lymphoid leukemia, and myelodysplastic syndrome patients after allogeneic stem cell transplantation from unrelated donors
Description: The purpose of this study is to find out if an investigational drug called US-ATG-F can be safely used to prevent graft versus host disease (GVHD)....MORE
___________________________________________________________________________________________________
 Number: 201202062 Principal Investigator: DiPersio, John
Title: A phase 1b study to evaluate the safety and preliminary Efficacy of pf-04449913, an oral hedgehog inhibitor, in Combination with intensive chemotherapy, low dose ara-c or Decitabine in patients with acute myeloid leukemia or high risk Myelodysplastic syndrome
Description: The purpose of this research study is to learn about the effects of the study drug, PF-04449913, in combination with chemotherapy, and to find the best dose of PF-04449913 for treating AML and high risk MDS....MORE
___________________________________________________________________________________________________
 Number: 201112110 Principal Investigator: Westervelt, Peter
Title: A Phase 3, Multicenter, Randomized Study to Evaluate the Substitution of Marqibo® (Vincristine Sulfate Liposomes Injection, VSLI) for Standard Vincristine Sulfate Injection (VSI) in the Induction, Intensification, and Maintenance Phases of Combination Chemotherapy in the Treatment of Subjects >/= 60 Years Old with Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)
Description: The purposes of this research study are: To compare the overall survival in patients 60-years of age and older who are newly diagnosed with ALL and treated with a combination chemotherapy which includes either VSI or Marqibo To compare the side effects between the 2 chemotherapy treatment grou...MORE
___________________________________________________________________________________________________
 Number: 201109095 Principal Investigator: Uy, Geoffrey
Title: A Phase 2, Multicenter, Randomized, Open Label, Parallel-Group Study of a Lenalidomide (Revlimid®) Regimen or a Sequential Azacitidine (Vidaza®) plus Lenalidomide (Revlimid®) Regimen versus Conventional Care Regimens for Therapy of Older Subjects with Newly Diagnosed Acute Myeloid Leukemia
Description: The purpose of this study is to see if the drug lenalidomide alone or in combination with the drug azacitidine is safe and effective for use in people 65 years and older with AML. This study is being conducted to determine if these drugs will help patients with AML more than currently available tr...MORE
___________________________________________________________________________________________________
 Number: 201301154 Principal Investigator: Dehdashti, Farrokh
Title: Imaging of Patients after Infusion of Haploidentical Genetically Modified T cells: A Pilot Study of Tracking and Toxicity and a companion to the protocol: “TK008: Randomized phase III trial of haploidentical HCT with or without an add back strategy of HSV-Tk donor lymphocytes in patients with high risk acute leukemia
___________________________________________________________________________________________________
 Number: 201011766 Principal Investigator: Westervelt, Peter
Title: Tissue Acquisition for Analysis of Genetic Progression Factors in Hematologic Diseases
___________________________________________________________________________________________________
 Number: 201102097 Principal Investigator: DiPersio, John
Title: Part I of an Assessment of Allogeneic Hematopoietic Stem Cell Transplantation in Medicare Beneficiaries with Myelodysplastic Syndrome and Related Disorders
___________________________________________________________________________________________________